Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism

• Status: Unknown status
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of the genetic Cyp 450 3A5 polymorphism of the recipient.

The study of the tacrolimus through level (ng/ml) determines if the therapeutic level is reached.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université Catholique de Louvain
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• First or second Kidney Transplantation from deceased or living donor

Exclusion Criteria:

• Donor age < 5 years.

• Patients who require plasma exchange because of high immunological risk